Clinical guideline
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.
J Clin Oncol · 2025
Studies and guidelines: Multiple myeloma
20 items with a structured summary · Multiple myeloma: the complete guide
Clinical guideline
Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
The Lancet Haematology · 2022
Clinical guideline
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group
The Lancet Oncology · 2021
Clinical guideline
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Annals of Oncology · 2021
Review article
Advances in multiple myeloma: key updates from the ASH 2025 meeting
J Hematol Oncol · 2026
Conversion from persistent MRD-positive to MRD-negative in all evaluable patientsIMMUNOPLANT (MRD-adapted consolidation in NDMM)
Other
MajesTEC-3: Redefining what’s possible in multiple myeloma
Clinical Hematology International · 2026
Clinical trial · Phase 3
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses.
Blood · 2024
13.8 vs 4.4 monthsMedian progression-free survival (final analysis)
Clinical trial · Phase 1
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
N Engl J Med · 2022
70%Response rate, 405 µg/kg weekly (median follow-up 11.7 months)
Clinical trial · Phase 3
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study
The Lancet Oncology · 2018
HR 0.98 (95% CI 0.85–1.14)Time to first skeletal-related event (denosumab vs zoledronic acid)
Clinical trial · Phase 3
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
N Engl J Med · 2017
50 months vs 36 months (transplantation vs RVD alone)Median progression-free survival
Observational study
Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
N Engl J Med · 2007
276 patientsNumber of patients meeting the criteria over the 26-year period
Observational study
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
N Engl J Med · 2002
115 of 1384 patients over 11,009 person-years of follow-upProgression of MGUS during follow-up
Clinical trial · Phase 3
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma
N Engl J Med · 2025
63.1% vs 40.8%5-year progression-free survival
Clinical trial · Phase 3
Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.
Nat Med · 2025
60.9% vs 39.4%MRD negativity (10⁻⁵)
Clinical trial · Phase 3
Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes.
Leukemia · 2025
61.9 vs 34.4 monthsMedian progression-free survival
Clinical trial · Phase 3
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.
Lancet Oncol · 2026
Not reached vs 11.8 monthsMedian progression-free survival
Other
Teclistamab plus daratumumab significantly boosts survival for patients with early RRMM
Cancer · 2026
Clinical trial · Phase 3
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
N Engl J Med · 2024
63.2% vs 45.2%60-month progression-free survival
Clinical trial · Phase 2
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Nat Med · 2023
61.0%Objective response rate
Clinical trial · Phase 3
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
N Engl J Med · 2019
70.6% vs 55.6%30-month progression-free survival
Nothing found.